Inclusion Criteria:

- Muscle invasive urothelial cancer (front line or following the progression of a
superficial tumor), pT2-pT3 stage without lymphatic impairment (N0) and without
detectable metastases (M0). An optimal macroscopic resection (TURB) have to be
performed

- The proof of invasive tumor to the muscle should be brought by a transurethral
resection under anaesthesia less than 8 weeks before or, in the absence, by
superficial biopsies and formal imaging. Multiples biopsies in the bladder must also
be performed.

- Age ≥ 18 years

- Life expectancy ≥ 6 months

- Kanorfsky index ≥ 70 % (WHO 0, 1, 2)

- Biological criteria: neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3, haemoglobin ≥
10 g/dl, creatinine clearance > 60 ml/mn

- No distant metastases (Thorax, abdomen, and pelvic CT-scan, bone scan)

- Efficient contraception for premenopausal women, maintained during the whole
treatment and up to two months after the completion of radiotherapy.

- No radiotherapy or chemotherapy history except for in situ bladder lesions.

- No carcinological history except for non melanoma skin tumours, in situ uterine
cervix cancer

- No contraindication to gemcitabine or cisplatin.

- No contraindication to radiotherapy

- Information letter and informed consent signed

- Patient covered by social security

Exclusion Criteria:

- Bladder tumors without any muscle infiltration

- Epidermoid carcinoma or adenocarcinoma

- Distance metastases or extrapelvic node positivity

- Severe digestive history (ulcerative colitis, complicated diverticulitis)

- Pregnancy and breast feeding